Program
mosliciguat
Also written as “Mosliciguat”, “inhaled mosliciguat” and “14C mosliciguat”.
Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pulmovant | 43 open or running | phase 3since Sep 7, 2026 | Oct 8, 2024 | Dec 2026phase 2 · NCT07333183 |
| Bayer | 10 open or running | phase 1since Nov 23, 2018 | Nov 23, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2018First study: phase 1 study in Hypertension, PulmonaryNew to BayerBayer · NCT03754660 · 38 enrolled · Austria, Czechia, Germany and more
- Oct 8, 2024Pulmovant's first study: phase 2 study in Hypertension, PulmonaryNew to PulmovantPulmovant · NCT06635850 · 135 enrolled · United States, Argentina, Australia and more
- Sep 12, 2025Phase 1 study in Healthy VolunteerPulmovant · NCT07185321 · 8 enrolled · United States
- Jan 8, 2026Phase 2 study in Hypertension, PulmonaryPulmovant · NCT07333183 · 20 planned · United States
- Sep 7, 2026Phase 3 study in Hypertension, PulmonaryPhase 3 reachedPulmovant · NCT07816185 · 376 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Hypertension, PulmonaryPulmovant · NCT07333183
- Jan 28, 2029Primary completion: phase 3 study in Hypertension, PulmonaryPulmovant · NCT07816185
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07816185Hypertension, Pulmonary · United States | 3 | Recruiting | Pulmovant | Jan 28, 2029 | 376 |
| NCT07333183Hypertension, Pulmonary · United States | 2 | Recruiting | Pulmovant | Dec 2026 | 20 |
| NCT07185321Healthy Volunteer · United States | 1 | Completed | Pulmovant | Jun 30, 2025 | 8 |
| NCT06635850Hypertension, Pulmonary · United States, Argentina, Australia and more | 2 | Active, not recruiting | Pulmovant | May 26, 2026 | 135 |
| NCT03754660Hypertension, Pulmonary · Austria, Czechia, Germany and more | 1 | Completed | Bayer | Apr 24, 2022 | 38 |
How it is read
Names in the registry
- “Mosliciguat”, 3 entries
- “inhaled mosliciguat”, 1 entry
- “14C mosliciguat”, 1 entry
- “BAY1237592”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, Pulmonary, 3 studies
- Pulmonary Arterial Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.